Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Medicare may cover Skyrizi (risankizumab-rzaa) if you have a plan with prescription drug benefits, such as a Part D or Medicare Advantage (Part C) plan. Skyrizi is a brand-name, biologic drug that ...

MONTREAL, March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative ...

The medical and healthcare industry is one of the largest globally, with a steady demand for products and services due to the biological nature of humans. Stocks like Pfizer Inc. (NYSE:PFE) and Tenet ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best medical stocks to buy now.

The season of Skyrizi continues as the treatment for psoriasis, Crohn’s disease and psoriatic arthritis from AbbVie notched the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands.

AbbVie share price is nearing the important resistance at $200. The company's Humira sales have continued falling after its patent expiry. It has new blockbuster drugs like Skyrizi and Rinvoq. AbbVie ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

In studies, the injected medicine helped a significant number of people with UC find relief from moderate to severe symptoms. The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as ...

The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This approval makes it the ...